Simoctocog Alfa

Summary

Simoctocog Alfa (CHEMBL2108319) is an approved protein; indicated across 1 condition including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108319
Name	Simoctocog Alfa
Type	Protein
Max phase	4

Also known as: Human-cl rh fviii, Nuwiq, Simoctocog alfa, Vihuma, SIMOCTOCOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05935358	PHASE4	RECRUITING	Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
NCT05936580	PHASE4	RECRUITING	Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
NCT04023019	Not specified	RECRUITING	Treatment of Hemophilia A Patients With FVIII Inhibitors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).